Evidence map›Paper›PMID 40118805›Full record

Observational studyJournal of the American Heart Association2025

An International Longitudinal Natural History Study of Patients With Danon Disease: Unique Cardiac Trajectories Identified Based on Sex and Heart Failure Outcomes.

Kimberly N Hong, Emily Eshraghian, Tarek Khedro, Alessia Argirò, Jennifer Attias, Garrett Storm, Melina Tsotras, Tanner Bloks, Isaiah Jackson, Elijah Ahmad and 7 more

Registry-linked trialAbstract readObservational Study
In one paragraph

Observational study in Journal of the American Heart Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03766386 (The Natural History of Danon Disease), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03766386 unknown statusnot on this map

The Natural History of Danon Disease

Typeobservational_patient_registrySponsorUniversity of California, San DiegoRan2018 to 2024Enrolled200ConditionsDanon Disease
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Kimberly N HongUniversity of California, San Diego La Jolla CA.ORCID 0000-0003-3293-138X
Emily EshraghianUniversity of California, San Diego La Jolla CA.ORCID 0000-0003-1852-3080
Tarek KhedroUniversity of California, San Diego La Jolla CA.ORCID 0000-0002-3965-3442
Alessia ArgiròUniversity of California, San Diego La Jolla CA.ORCID 0000-0002-6394-9948
Jennifer AttiasUniversity of California, San Diego La Jolla CA.
Garrett StormUniversity of Colorado Anschutz Medical Center Denver CO.ORCID 0000-0003-1248-1449
Melina TsotrasUniversity of California, San Diego La Jolla CA.
Tanner BloksUniversity of Colorado Anschutz Medical Center Denver CO.
Isaiah JacksonUniversity of Colorado Anschutz Medical Center Denver CO.
Elijah AhmadUniversity of Colorado Anschutz Medical Center Denver CO.
Sharon GrawUniversity of Colorado Anschutz Medical Center Denver CO.
Luisa MestroniUniversity of Colorado Anschutz Medical Center Denver CO.ORCID 0000-0003-1116-2286
Quan M BuiUniversity of California, San Diego La Jolla CA.ORCID 0000-0001-6070-6978
Jonathan SchwartzRocket Pharmaceuticals Inc. New York NY.ORCID 0000-0002-2211-4151
Stuart TurnerRocket Pharmaceuticals Inc. New York NY.
Eric D AdlerUniversity of California, San Diego La Jolla CA.ORCID 0000-0002-4765-0188
Matthew TaylorUniversity of Colorado Anschutz Medical Center Denver CO.ORCID 0000-0001-9043-0810

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDanon disease is a rare X-linked dominant cardioskeletal myopathy caused by mutations in the lysosome-associated membrane protein-2 gene. Though the severe morbidity of disease in men is well established, longitudinal studies describing the trajectory of cardiovascular disease in both sexes are lacking. METHODS AND

resultsData were from the International Danon Disease Registry and includes retrospective data on 116 patients who provided informed consent between 2005 and 2022. The analysis included 116 patients with Danon disease with a median age of diagnosis of 15.2 years (10.0-25.2 years). Trends in echocardiographic parameters over time indicate decreased left ventricular ejection fraction and increased left ventricular end diastolic dimension regardless of sex and heart failure (HF) outcome; however, rate of change was increased in patients who experienced a HF outcome in both sexes. Left ventricular wall hypertrophy continues in men who have not yet experienced a HF outcome and stabilizes before HF outcome, while females have progressive left ventricular thinning regardless of HF outcome. Stratified analysis demonstrated 2 distinct groups of females: one who experienced HF outcome before 26 years of age and another group with this HF outcome after.

conclusionsIn this largest longitudinal natural history study of Danon disease to date, we confirmed that males present on average a decade earlier and demonstrate more progressive cardiac hypertrophy and HF than females. Notably, there may be a subset of females who are phenotypically similar to males with profound left ventricular hypertrophy that appears to stabilize or regress before HF outcome. Correlations between structural cardiac dysfunction and disease progression may permit risk stratification, refinement of treatment algorithms, and inform therapeutic trial design. REGISTRATION: URL: https://clinicaltrials.gov/; Unique Identifier: NCT03766386.

Indexed as

Glycogen Storage Disease Type IIbHeart FailureHypertrophy, Left VentricularVentricular Function, LeftAdolescentAdultChildDisease ProgressionEchocardiographyFemaleHumansLongitudinal StudiesMalePrognosisRegistriesRetrospective StudiesDanon diseasegenetic cardiomyopathyheart failure

Identifiers

PMID40118805
PMCPMC12132809

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.